IRIS Accounts Production v26.1.10.61 08696340 director 1.1.25 31.12.25 31.12.25 false true false false true false iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh 08696340 2024-12-31 08696340 2025-12-31 08696340 2025-01-01 2025-12-31 08696340 2023-12-31 08696340 2024-01-01 2024-12-31 08696340 2024-12-31 08696340 ns15:EnglandWales 2025-01-01 2025-12-31 08696340 ns14:PoundSterling 2025-01-01 2025-12-31 08696340 ns10:Director1 2025-01-01 2025-12-31 08696340 ns10:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 08696340 ns10:SmallEntities 2025-01-01 2025-12-31 08696340 ns10:AuditExempt-NoAccountantsReport 2025-01-01 2025-12-31 08696340 ns10:SmallCompaniesRegimeForDirectorsReport 2025-01-01 2025-12-31 08696340 ns10:SmallCompaniesRegimeForAccounts 2025-01-01 2025-12-31 08696340 ns10:FullAccounts 2025-01-01 2025-12-31 08696340 ns10:RegisteredOffice 2025-01-01 2025-12-31 08696340 ns5:CurrentFinancialInstruments 2025-12-31 08696340 ns5:CurrentFinancialInstruments 2024-12-31 08696340 ns5:ShareCapital 2025-12-31 08696340 ns5:ShareCapital 2024-12-31 08696340 ns5:SharePremium 2025-12-31 08696340 ns5:SharePremium 2024-12-31 08696340 ns5:RetainedEarningsAccumulatedLosses 2025-12-31 08696340 ns5:RetainedEarningsAccumulatedLosses 2024-12-31

REGISTERED NUMBER: 08696340 (England and Wales)

| BIOTECNOL LIMITED |

| UNAUDITED FINANCIAL STATEMENTS |

| FOR THE YEAR ENDED 31 DECEMBER 2025 |

| BIOTECNOL LIMITED (REGISTERED NUMBER: 08696340) |

CONTENTS OF THE FINANCIAL STATEMENTS

for the Year Ended 31 December 2025

Page |

| Company Information | 1 |

| Statement of Financial Position | 2 |

| Notes to the Financial Statements | 3 |

| BIOTECNOL LIMITED |

COMPANY INFORMATION

for the Year Ended 31 December 2025

| DIRECTOR: | Dr P M D C De Noronha Pissarra

| REGISTERED OFFICE: | 6th Floor

| 1 London Wall

| London

| EC2Y 5EB

| REGISTERED NUMBER: | 08696340 (England and Wales)

| ACCOUNTANTS: | Miller & Co

| Chartered Accountants

| 5 Imperial Court

| Laporte Way

| Luton

| Bedfordshire

| LU4 8FE

| BIOTECNOL LIMITED (REGISTERED NUMBER: 08696340) |

STATEMENT OF FINANCIAL POSITION

31 December 2025

| 2025 |  | 2024

| Notes | £ | £ |

CURRENT ASSETS

Cash at bank | 13,051 |  | 21,847 |  |

CREDITORS

Amounts falling due within one year | 4 | 955 |  | 910 |  |

NET CURRENT ASSETS | 12,096 |  | 20,937 |  |

TOTAL ASSETS LESS CURRENT LIABILITIES | 12,096 |  | 20,937 |  |

CAPITAL AND RESERVES

Called up share capital | 7,025 |  | 7,025 |  |

Share premium | 2,561,685 |  | 2,561,685 |  |

Retained earnings | (2,556,614 | ) | (2,547,773 | ) |

SHAREHOLDERS' FUNDS | 12,096 |  | 20,937 |  |

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2025 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

(a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the director and authorised for issue on 30 July 2026 and were signed by:

Dr P M D C De Noronha Pissarra - Director

| BIOTECNOL LIMITED (REGISTERED NUMBER: 08696340) |

NOTES TO THE FINANCIAL STATEMENTS

for the Year Ended 31 December 2025

1. | STATUTORY INFORMATION

| Biotecnol Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. | ACCOUNTING POLICIES

| Accounting convention

| These financial statements have been prepared in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other then where additional disclosure is required to show a true and fair view.

| The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these statement are rounded to the nearest £.

| The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

| Transitional relief

| On transition to FRS102 from previous UK GAAP the company took advantage of transitional relief as follows:

| Share based payment transactions

| The company has elected not to apply section 26 share based payment to equity Instruments granted before the start of the first reporting period that complies with this accounting standard. Financial Reporting Standard for Smaller Entities (effective January 2015) has been applied to instruments granted in the prior period.

| The company has taken advantage of the exemption under section 399 of the Companies Act 2006 not to prepare consolidated accounts on the basis that the group of which this is the parent qualifies as a small group. The financial statements present information about the company as an individual entity and not about its group.

| Going concern

| The financial statements have been prepared on the going concern basis which is considered appropriate by the director.

| BIOTECNOL LIMITED (REGISTERED NUMBER: 08696340) |

NOTES TO THE FINANCIAL STATEMENTS - continued

for the Year Ended 31 December 2025

2. | ACCOUNTING POLICIES - continued

| Financial instruments

| The company has elected to apply the provisions of Section 11 'Basic financial Instruments' and Section 12 'Other Financial Instruments' of FRS 102 to all of its financial instruments.

| Financial Instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

| Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

| Basic financial assets

| Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

| Classification of financial liabilities

| Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

| Basics financial liabilities

| Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

| Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

| Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

| Compound instruments

| The component parts of compound instruments issued by the company are classified separately as financial liabilities and equity in accordance with the substance of the contractual arrangement. At the date of issue, the fair value of the liability component is estimated using the prevailing market interest rate for a similar non-convertible instrument. This amount is recorded as a liability on an amortised cost basis using the effective interest method until extinguished upon conversion or at the instrument's maturity date. The equity component is determined by deducting the amount of the liability component from the fair value of the compound instrument as a whole. This is recognised and included in equity net of income tax effects and is not subsequently remeasured.

| Equity instruments

| Equity instruments issued by the company are recorded at the proceeds received, net of direct issue costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

| BIOTECNOL LIMITED (REGISTERED NUMBER: 08696340) |

NOTES TO THE FINANCIAL STATEMENTS - continued

for the Year Ended 31 December 2025

2. | ACCOUNTING POLICIES - continued

| Taxation

| Current tax represents the amount of tax payable or receivable in respect of the taxable profit (or loss) for the current or past reporting periods. It is measured at the amount expected to be paid or recovered using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

| Deferred tax represents the future tax consequences of transactions and events recognised in the financial statements of current and previous periods. It is recognised in respect of all timing differences, with certain exceptions. Timing differences are differences between taxable profits and total comprehensive income as stated in the financial statements that arise from the inclusion of income and expense in tax assessments in periods different from those in which they are recognised in the financial statements. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

| Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date that are expected to apply to the reversal of timing differences. Deferred tax on revalued non-depreciable tangible fixed assets and investment properties is measured using the rates and allowances that apply to the sale of the asset.

| Foreign currencies

| Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation are included in the profit and loss account for the period.

| Impairment of fixed assets

| At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

| Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in sue, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risk specific to the asset for which the estimates of future cash flows have not been adjusted.

| If the recoverable amount of an asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

| Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

| Employee benefits

| The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

| The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

| Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

| BIOTECNOL LIMITED (REGISTERED NUMBER: 08696340) |

NOTES TO THE FINANCIAL STATEMENTS - continued

for the Year Ended 31 December 2025

2. | ACCOUNTING POLICIES - continued

| Share-based payments

| Equity-settled share-based payments granted after 1 January 2016 are measured at fair value at the date of grant by reference to the fair value of the equity instruments granted using the Black Scholes model. The fair value determined at the grant date is expensed on a straight-line basis over the vesting period, based on the estimate of shares that will eventually vest. A corresponding adjustment is made to equity.

| For equity instruments granted before the start of the first reporting period to comply with the new accounting standards (1 January 2016), the transitional relief available under FRS 102 to not apply Section 26 Share Based Payments to such instruments has been applied. As such these share based payments are not recognised in the financial statements and are disclosed in note 7.

3. | EMPLOYEES AND DIRECTORS

| The average number of employees during the year was 1 (2024 - 1 ) .

4. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Other creditors | 955 |  | 910 |  |

5. | PARENT COMPANY

| There is no ultimate controlling party.

6. | SHARE-BASED PAYMENT TRANSACTIONS

| The company operates share option plans under which 1,000,000 options have been granted to the director at an exercise price of £0.01. The options can be exercised at any time in the 10 years commencing from the grant date, that being 16th April 2015.

| No options were granted, lapsed or exercised in the current period.

| As share option plans currently in place were granted before the current period, the directors have used the transitional relief available under FRS102 to not apply Section 26 Share Based Payments to equity instruments granted before the start of the first reporting period that complies with the new accounting standard.

| The number of granted share options outstanding at the year end were 1,000,000 (2024: 1.000.000) at a weighted average exercise price of £0.01 (2024: £0.01)

| The exercisable share options at the year end were 1,000,000 (2024: 1.000.000) at a weighted average exercise price of £0.01 (2024: £0.01).